New combo attack on lung cancer brain metastases shows promise in Real-World study
NCT ID NCT07491211
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at using a targeted drug called osimertinib together with precise brain radiation as the first treatment for people with a certain type of lung cancer (EGFR-mutant) that has spread to the brain and causes symptoms. Researchers reviewed medical records of 300 patients from multiple hospitals to see how well this combination works and how safe it is. The goal is to find a better way to control both the lung cancer and brain tumors from the start.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Osimertinib (a targeted cancer pill) and intracranial stereotactic radiotherapy (precise radiation to brain tumors)
- What this could lead to
- If successful, this combination could become a standard first treatment for people with EGFR-mutant lung cancer that has spread to the brain, potentially improving control of brain tumors and extending survival.
- What could go wrong
- This is a retrospective study, not a controlled trial, so results may be less reliable. The treatment involves radiation to the brain, which carries risks like swelling or tissue damage. It is also only for patients with a specific gene mutation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, China, 200032, China
-
Shanghai Jiao Tong University Affiliated Chest Hospital
Shanghai, China
-
Wuhan Tongji Hospital
Wuhan, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo outsmart tough lung cancer?
- Can a new Antibody-Drug conjugate outsmart advanced lung cancer?
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
- Drug duo aims to tackle tough lung cancers after first treatment fails
- Blood test may let cancer patients take safe breaks from immunotherapy
- New combo aims to stall lung cancer when targeted pills start to fail